Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06091748
PHASE3
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
View on ClinicalTrials.gov
Summary
This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
Official title: An Open-label, Single Arm Clinical Trial of Gallium (68Ga) Edotreotide PET-CT Scan for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2024-02-22
Completion Date
2025-11-01
Last Updated
2025-06-03
Healthy Volunteers
Yes
Interventions
DRUG
68Ga-DOTATOC
Detection of somatostatin positive lesions in GEP-NETs
Locations (1)
Beijing Cancer Hospital
Beijing, Beijing Municipality, China